Full Text Full Text (PDF) CME: Take the course for this article: Major Depressive Disorder and Suicide Citation Map Email this article to a Colleague Similar articles in this journal Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Miller, A. H. Articles by Raison, C. L. Search for Related Content Articles by Miller, A. H. Articles by Raison, C. L.

Immune System Contributions to the Pathophysiology of Depression

Correspondence: Address correspondence to Andrew H. Miller, M.D., William P. Timmie Professor of Psychiatry and Behavioral Sciences, and Director, Psychiatric Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road, 5th floor, Atlanta, GA 30322; amill02{at}emory.edu.

Major depression is a devastating disorder that represents a major public health concern. Of special relevance is the high percentage of patients whose depression does not respond to or who are unable to tolerate conventional antidepressant medications, which primarily target monoamine neurotransmission. Recent data indicate that the immune system may play a role in the pathophysiology of depression, representing a novel pathway for therapeutic development. Patients with major depression have been found to exhibit evidence of an activated innate immune response as reflected by increased biomarkers of inflammation, including innate immune cytokines, acute-phase proteins, chemokines, and adhesion molecules. In addition, administration of innate immune cytokines to laboratory animals and humans has been shown to induce behavioral changes that significantly overlap with the symptom criteria of major depression. Treatment of patients with inflammatory disorders using anticytokine therapies has also been found to reduce depressive symptoms. Interestingly, psychosocial stress, a well-known precipitant of depressive disorders, has been shown to activate the innate immune response. Finally, innate immune cytokines have been shown to influence virtually every pathophysiological domain relevant to depression including monoamine neurotransmission, neuroendocrine function, synaptic plasticity, and regional brain metabolism. Of note, a response to conventional antidepressant medications is associated with a decrease in inflammatory biomarkers, whereas patients with treatment-resistant depression are more likely to exhibit evidence of increased inflammation. Taken together, these data provide the foundation for considering an activated innate immune response as a potential target for further study and therapeutic development in mood disorders, especially in the context of treatment resistance.

CME Disclosure

Andrew H. Miller, M.D., Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.

Consultant and Grant Recipient: Schering-Plough. Consultant: GlaxoSmithKline, Centacor.

Charles L. Raison, M.D., Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.

Speakers Bureau, Advisory Board: Wyeth, Lilly, Schering-Plough.

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us